Clinical trials: Elevated Risk of Cardiovascular Disease
Obesity, Visceral, Cardiovascular Diseases
Impact of Liraglutide 3.0 on Body Fat Distribution
This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks…
- Conditions
- Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
- Trial name
- NCT03038620
- Testing
- Liraglutide
- Where
- United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Insulinemic Response, Type 2 Diabetes (Adult Onset)
Impact of High-Oleic Palm Oil Consumption on Cardiovascular Biomarkers in Adults in Bogotá
This randomized clinical trial aims to evaluate the effects of refined high-oleic palm oil consumption on cardiovascular risk biomarkers and insulin resistance in healthy adults.
- Conditions
- Insulinemic Response, Type 2 Diabetes (Adult Onset), Hyperglycaemia (Diabetic), Hyperlipidaemia
- Trial name
- EDCHOPA-CRB (NCT07748559)
- Testing
- High-oleic palm oil
- Where
- Colombia
- Volunteers
- 52 people
- Sponsor
- Ruby Alejandra Villamil
Multiple Myeloma
Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma
This is an open-label, phase 1 study to assess the safety, pharmacodynamics, and anti-myeloma effects of autologous T cells expressing BCMA (B-cell maturation antigen)-specific chimeric antigen receptors with tandem TCRζ and…
- Trial name
- NCT03549442
- Testing
- BCMA CART + huCART19, CART BCMA or CART BCMA + huCART19, Single-dose infusion of CART BCMA or CART BCMA + huCART19
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pennsylvania
Intracranial Aneurysm, Inflammation Vascular
Statin Treatment for UnruptureD Intracranial anEurysms Study
This study was designed to identify whether there is a measurable reduction in inflammation in walls of intracranial aneurysms with oral atorvastatin.
- Trial name
- STUDIES (NCT04149483)
- Testing
- Atorvastatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Neurosurgical Institute
Fall, Congestive Heart Failure
Reducing High-Risk Geriatric Polypharmacy Via EHR Nudges: Pilot Phase
Polypharmacy is common among older adults in the United States and is associated with harms such as adverse drug reactions and higher costs of care.
- Conditions
- Fall, Congestive Heart Failure, Chronic Kidney Failure, Adverse Drug Event
- Trial name
- NCT03791580
- Testing
- Commitment nudge, Justification nudge
- Where
- United States
- Sponsor
- RAND
Hypercholesteremia
Observational to Investigate the Efficacy of CRESTOR 5mg in Reaching LDL-C Target Goals in Patients Who Are at High Risk for a Cardiovascular Event
Observational study to investigate the use and efficacy of CRESTOR 5 mg in reaching LDL-C target goals in both statin naïve and statin treated primary and secondary prevention patients at high risk for a cardiovascular event.
- Trial name
- NCT00347217
- Where
- 215 sites in Netherlands
- Volunteers
- 3,840 people
- Sponsor
- AstraZeneca
Venous Thromboembolism, Patient-Centered Care
Anticoagulation Medical Home
The primary study goal is to improve the quality of care transitions for patients with new episodes of venous thromboembolism (VTE).
- Trial name
- NCT02870296
- Testing
- Enhanced Assessment and Education
- Where
- United States
- Volunteers
- 162 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Major hæmorrhage
Early Versus Late Resumption of Anticoagulation in Patients With Both High Thrombosis Risk and Major HEmoRrhage
In patients with a high thromboembolic risk, withdrawing anticoagulant treatment is recommended in some situations, including when major hæmorrhage occurs. But withdrawing treatment can be risky.
- Trial name
- RATHER (NCT02091479)
- Testing
- UFH Early group, UFH Late group
- Where
- 2 sites in France
- Volunteers
- 14 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Hypercholesterolemia
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe on Top of Statin in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY COMBO II)
Alirocumab (SAR236553/REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9).
- Trial name
- NCT01644188
- Testing
- Alirocumab, Ezetimibe, Lipid Modifying Therapy (LMT)
- Where
- 126 sites in United States, Canada and 8 more
- Volunteers
- 720 people
- Sponsor
- Sanofi
Hypercholesterolemia
Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)
This is a randomized, double-blind, double-dummy, active-controlled, parallel-group, multi-national, multi-center study to compare alirocumab (REGN727/SAR236553) versus ezetimibe in participants with primary hypercholesterolemia…
- Trial name
- NCT01709513
- Testing
- Atorvastatin, Ezetimibe, Alirocumab
- Where
- 70 sites in United States, Austria and 6 more
- Volunteers
- 314 people
- Sponsor
- Regeneron Pharmaceuticals
Hypertension, Diabetes
Wearable Devices Empowering Active Health Initiatives for High-Risk Stroke Populations
The purpose of this study is to evaluate the control effect of smart wearable devices on key risk factors in the high-risk populations for stroke
- Conditions
- Hypertension, Diabetes, Atrial Fibrillation, Dyslipidemia
- Trial name
- AISP (NCT06935513)
- Testing
- Wearable Devices
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Affiliated Hospital of Nantong University
Acute Myocardial Infarction, Heart Failure
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and…
- Trial name
- PRESTIGE-AMI (NCT04899479)
- Testing
- SGLT2 inhibitor, Control
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Heart Failure
Remote Monitoring in Patients With Heart Failure
This study is a prospective cohort study with consecutive enrollment of newly diagnosed heart failure patients, investigating the prevalence and types of arrhythmias in this high-risk population using non-invasive remote…
- Trial name
- REM-HF (NCT04537104)
- Testing
- Coala Heart Monitor
- Where
- Denmark
- Volunteers
- 130 people
- Sponsor
- Herlev and Gentofte Hospital
Coronary Artery Disease
Cruz HBR Registry - Post-market Registry to Evaluate the Safety and Efficacy of the Supraflex Cruz Stent
This is a prospective, multicenter, open-label, single-arm registry. The primary objective of this registry is to confirm the results of the Supraflex Cruz stent in real life all-comer patients (800 patients as in the Supraflex…
- Trial name
- NCT04138238
- Testing
- Supraflex Cruz Sirolimus-eluting Stent
- Where
- 26 sites in France, Germany and 1 more
- Volunteers
- 1,200 people
- Sponsor
- Sahajanand Medical Technologies Limited
Aortic Stenosis, Symptomatic Aortic Stenosis
China S3: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 THV in the Chinese Population
To evaluate the safety and effectiveness of the SAPIEN 3 (Edwards Lifesciences, Irvine, California) transcatheter heart valve implantation (TAVI) in Chinese patients with symptomatic severe calcific aortic stenosis who are…
- Conditions
- Aortic Stenosis, Symptomatic Aortic Stenosis, Aortic Regurgitation
- Trial name
- NCT03466918
- Testing
- SAPIEN 3 THV with the Commander delivery system
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Edwards Lifesciences
Cardiovascular Diseases
The Usefulness of the HyperQ Stress System in Routine Annual Screening Testing
The main objective of this study is to compare the sensitivity and specificity of a new system for analyzing the electrocardiogram (ECG) to the sensitivity and specificity of a conservative treadmill test in asymptomatic…
- Trial name
- NCT00266435
- Where
- Israel
- Volunteers
- 371 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Cardiovascular Diseases, Microvascular Complications
Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study
Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis…
- Trial name
- NCT07359768
- Where
- Sweden
- Volunteers
- 900 people
- Sponsor
- HJN Sverige AB/Neko Health
Diabetes Mellitus, Type 2, Obesity
Microclinic Social Network Behavioral Health Trial in Jordan
This 3-armed randomized controlled trial aims to evaluate the effectiveness of The Microclinic Behavioral Health Program in improving obesity and diabetes risk factors through a behavioral intervention program structured to…
- Conditions
- Diabetes Mellitus, Type 2, Obesity, Hypertension, Hyperglycemia
- Trial name
- NCT01818674
- Testing
- Microclinic Behavioral Health Full Program (education curriculum in classroom setting, plus full social interaction program), Microclinic Behavioral Health Basic Program (education-only in classroom setting; no structured social interactions)
- Where
- 3 sites in Jordan
- Volunteers
- 914 people
- Sponsor
- Microclinic International
Dyslipidemia
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
The primary objective was to evaluate the effect of treatment with evolocumab, compared with placebo, on the risk for cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary…
- Trial name
- FOURIER (NCT01764633)
- Testing
- Evolocumab
- Where
- 1,284 sites in United States, Argentina and 47 more
- Volunteers
- 27,564 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.